Xencor (XNCR) Stock Forecast & Price Target

Xencor is a promising clinical-stage biopharmaceutical company with a strong pipeline of engineered antibody therapeutics targeting cancer and autoimmune diseases. The company's recent 2Q26 earnings report and program updates, along with the upcoming release of ccRCC expansion data for XmAb819 at ESMO in October and plans for registration-enabling studies in 2027, suggest positive momentum and potential for improved response rates. While there are risks to consider, such as potential clinical trial failures or low sales, Xencor's focus on meaningful therapies and its efforts to explore combinations put the company in a good position for future success.

Xencor is facing challenges with limited data and potential safety concerns for its key pipeline product, XmAb819, in combination with a PD-1 inhibitor. The company also has a reliance on collaboration and licensing agreements for revenue, as opposed to the success of its own drug sales. With only a diversified set of catalysts expected in the short term, there may not be enough positive momentum to support a significant increase in the stock's value.